Merck KGaA, Pfizer's immuno-drug shown to alleviate kidney cancer

Merck KGaA said that its immunotherapy Bavencio, jointly developed with Pfizer, delayed the progression of kidney cancer when used in combination with Pfizer's Inlyta drug in a late-stage study.

from Reuters: Health https://ift.tt/2NxYAgV